The challenge of treating Lentigo Maligna (LM); An international multicentre randomised trial comparing radiation therapy to imiquimod for patients diagnosed with complex LM — ASN Events

The challenge of treating Lentigo Maligna (LM); An international multicentre randomised trial comparing radiation therapy to imiquimod for patients diagnosed with complex LM — ASN Events

The challenge of treating Lentigo Maligna (LM); An international multicentre randomised trial comparing radiation therapy to imiquimod for patients diagnosed with complex LM

The challenge of treating Lentigo Maligna (LM); An international multicentre randomised trial comparing radiation therapy to imiquimod for patients diagnosed with complex LM (#309)

Pascale Guitera ¹ ² ³ , Gerald Fogarty ¹ ⁴ ⁵ , Angela Hong ¹ ² ³ ⁵ , Elizabeth Paton ⁵ , Hendra Wijaya ⁵ , Patricia Li ⁵

Melanoma Institute Australia, Sydney, NSW, Australia
Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, NSW, Australia
Department of Radiation Oncology, St Vincent's and Mater Hospitals, Sydney, NSW, Australia
Australia and New Zealand Melanoma Trials Group, Sydney, NSW, Australia

Publish consent withheld

Authors contributing to this presentation.

Guitera, P

Fogarty, G

Professor Gerald Fogarty is a radiation oncologist with an interest in skin and prostate cancer. He trained at the Peter MacCallum Cancer Centre, Australia’s largest cancer centre and has a PhD in the “Advances in the Radiotherapy treatment of Skin Cancer”. He is a senior radiation oncologist with Melanoma Institute of Australia (http://www.melanoma.org.au/), the largest melanoma centre in the world and the Skin and Cancer Foundation (http://www.scfa.edu.au/). He is the chief investigator of an International Phase III Trial with over $2 million in funding in the radiotherapy of melanoma and a principal investigator of other trials conducted by the Australian and New Zealand Melanoma Trials Group (https://anzmtg.org/) and Trans-Tasman Radiation Oncology Group (http://www.trog.com.au/). He is the Director of the Mater Sydney Radiotherapy Centre and is on staff at the St Vincent’s and Macquarie University Hospitals, Sydney. He also is currently the Master of Warrane College, UNSW. (http://warrane.unsw.edu.au/)

Hong, A

Paton, E

Wijaya, H

Li, P